# Scinai Immunotherapeutics Ltd. (SCNI)

Source page: https://stoqly.net/companies/scni

- **Ticker:** SCNI (Nasdaq)
- **Sector:** Health Care / Biological Products, (No Diagnostic Substances)
- **SEC CIK:** 0001611747
- **Latest annual report:** 20-F filed 2026-04-01 (https://www.sec.gov/Archives/edgar/data/1611747/000121390026038011/ea0283609-20f_scinai.htm)
- **Data updated:** 2026-11-01

## Key figures

- **Last close:** $0.47 on 2026-10-30 (−9.05% on the day)
- **Revenue (FY2025):** $1.3M
- **Revenue growth:** +99.2%
- **Gross margin:** −202.3%
- **Operating margin:** −575.3%
- **Net margin:** −633.6%
- **Free cash flow:** −$6.1M
- **Free cash flow margin:** −461.9%
- **Return on equity:** −91.9%
- **Change in share count:** +189.6%
- **Piotroski F-score:** 2/9
- **Insider buys, last 90 days:** $0.0M
- **Insider sells, last 90 days:** $0.0M

Definitions: https://stoqly.net/about

## Annual results

From SEC EDGAR XBRL filings. Full table: https://stoqly.net/companies/scni/figures.csv

| US$ millions | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---:|---:|---:|---:|---:|
| Revenue | — | — | — | 1 | 1 |
| Operating income | -11 | -11 | -10 | -9 | -8 |
| Net income | -8 | -6 | -7 | 5 | -8 |
| Diluted EPS (US$) | -0.02 | 0.01 | 0.00 | — | — |
| Operating cash flow | -7 | -7 | -9 | -6 | -6 |
| Free cash flow | -8 | -8 | -10 | -6 | -6 |
| Cash | 17 | 14 | 5 | 2 | 2 |
| Debt and leases | 0 | 0 | — | — | — |

---

Source: SEC EDGAR filings and end-of-day prices, via Stoqly. For information only — not investment advice or a recommendation to buy, sell or hold any security.